Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...

Investors are now eyeing the next major milestone for Inventiva, which is the expected release of topline results from the NATiV3 trial in the latter half of 2026. The company’s progress and the ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II ...

Greenwich LifeSciences (NASDAQ:GLSI) added ~23% in the premarket on Wednesday after the company posted preliminary immune ...

Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based ...

The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...